{"paper_id":"f3c17711-5f6a-4cee-a8ec-e1ad250f9d08","body_text":"ABSTRACT\nEndometriosis is a chronic inflammatory gynecological condition that significantly impacts women’s quality of life. Given the limitations of conventional therapies, complementary strategies are being explored. This randomized, double-blind, placebo-controlled clinical trial evaluated the safety and clinical effects of endovaginal medical ozone treatment as an adjuvant intervention in women with endometriosis. Thirty participants were allocated into placebo (OzP) and active treatment (OzA) groups. Weekly endovaginal applications were performed for 10 weeks. Clinical outcomes were assessed at baseline and post-treatment using the Numeric Pain Rating Scale (NPRS), Endometriosis Health Profile-30 (EHP-30), Female Sexual Function Index (FSFI), and Beck Anxiety Inventory (BAI). The OzA group demonstrated significant reductions in pain and improvements in quality of life, sexual function, and anxiety symptoms compared with OzP. No serious adverse events were observed, and the intervention showed a favorable tolerability profile. These findings suggest that endovaginal medical ozone treatment may represent a minimally invasive adjuvant strategy in endometriosis management.\nDisclosure statement\nNo potential conflict of interest was reported by the author(s).\nData availability statement\nThe datasets generated and analyzed during the current study are not publicly available due to ethical and privacy restrictions involving human participants. Data are available from the corresponding author upon reasonable request and subject to approval by the Institutional Research Ethics Committee.\nEthical approval\nThe study was approved by the Human Research Ethics Committee of Universidade Brasil (Plataforma Brasil, protocol 4,506,560) and registered in the Brazilian Clinical Trials Registry (ReBEC, RBR-10fhfdt4)","source_license":"CC0","license_restricted":false}